Gilead’s GS-9674 shows positive action in primary sclerosing cholangitis

Gilead’s GS-9674 shows positive action in primary sclerosing cholangitis

Submitted by admin on November 12, 2018 - 9:24am
Source: 
Pharmaceutical Business Review
News Tags: 
Gilead Sciences
GS-9674
primary sclerosing cholangitis
clinical trials
Headline: 
Gilead’s GS-9674 shows positive action in primary sclerosing cholangitis
snippet: 

Gilead Sciences announced that its GS-9674 has showed significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC) in a phase 2 trial.